1. Articles in category: Burden of Treatment

    1-24 of 154 1 2 3 4 5 6 7 »
    1. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    2. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    3. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    4. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    5. LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      Oncotarget. 2017 Sep 12;8(39):65620-65626

      Authors: Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, Yang L, Yan L

      Abstract Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility.

      Read Full Article
    6. NIH Funds Pediatric Data Resource Center.

      NIH Funds Pediatric Data Resource Center.

      Cancer Discov. 2017 Oct 11;:

      Authors:

      Abstract Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.

      PMID: 29021134 [PubMed - as supplied by publisher]

      Read Full Article
    7. Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      J Pediatr Surg. 2017 Sep 11;:

      Authors: Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G

      Abstract BACKGROUND/PURPOSE: The impact of abdominal topography and surgical technique on resectability and local relapse pattern of relapsed abdominal high-risk neuroblastoma (R-HR-NB) is not clearly defined.

      Read Full Article
      Mentions: Treatment Relapse
    8. Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Indian Pediatr. 2017 Sep 15;54(9):765-770

      Authors: Jain R, Gupta K, Bhatia A, Bansal A, Bansal D

      Abstract Veno-occlusive disease of the liver is mostly encountered as a complication of hematopoietic stem cell transplantation with myeloablative regimens with an incidence estimated to be 13.7%.

      Read Full Article
    9. Diet, exercise modifications can have ‘tremendous impact’ on pediatric cancer outcomes

      Joya Chandra Keri Schadler Diet and exercise may improve treatment outcomes among pediatric patients with cancer, according to a study conducted at The University of Texas MD Anderson Children’s Cancer Hospital. In addition, introducing energy balance interventions may reduce the risk for late effects during survivorship. Researchers at MD Anderson reviewed 67 pediatric oncology studies to evaluate the relationship between diet and exercise.

      Read Full Article
      Mentions: Treatment
    10. GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints.

      GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints.

      Cancer. 2017 Oct 04;:

      Authors: Wiles AB, Karrs JX, Pitt S, Almenara J, Powers CN, Smith SC

      Abstract BACKGROUND: Neuroblastomas (NBs) are the most common solid cancer of childhood and infancy; however, in poorly differentiated forms, they present diagnostic challenges.

      Read Full Article
    11. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      Clin Cancer Res. 2017 Sep 22;:

      Authors: Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL

      Read Full Article
    12. Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.

      Manipulation of variables in local controlled release vincristine treatment in neuroblastoma.

      J Pediatr Surg. 2017 Sep 04;:

      Authors: Coburn JM, Harris J, Cunningham R, Zeki J, Kaplan DL, Chiu B

      Abstract INTRODUCTION: Local drug delivery minimizes systemic toxicity while delivering high-dose chemotherapy for neuroblastoma patients. We hypothesized that varying burst and maintenance dosing of implanted silk platforms would improve survival.

      Read Full Article
    13. Therapeutic plasma exchange for a case of refractory opsoclonus myoclonus ataxia syndrome

      Opsoclonus myoclonus ataxia syndrome (OMAS) can be refractory to standard therapies and devastating. Alternative treatments are imperative. A 14-month-old male diagnosed with neuroblastoma and paraneoplastic OMAS achieved complete cancer remission with chemotherapy. The OMAS, however, persisted over the subsequent 4 years despite numerous immune-modulatory and immunosuppressive therapies.

      Read Full Article
    14. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies

      Background: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible.

      Read Full Article
      Mentions: Refractory
    15. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    16. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Int J Radiat Oncol Biol Phys. 2017 Oct 01;99(2):468-475

      Authors: Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG

      Read Full Article
    17. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

      Cochrane Database Syst Rev. 2017 Aug 25;8:CD010685

      Authors: Peinemann F, van Dalen EC, Enk H, Berthold F

      Abstract BACKGROUND: Neuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumours mainly develop in the adrenal medullary tissue, with an abdominal mass as the most common presentation.

      Read Full Article
      Mentions: INRG
    18. Diffusion-weighted MRI for differentiating Wilms tumor from neuroblastoma.

      Diffusion-weighted MRI for differentiating Wilms tumor from neuroblastoma.

      Diagn Interv Radiol. 2017 Aug 22;:

      Authors: Aslan M, Aslan A, Arıöz Habibi H, Kalyoncu Uçar A, Özmen E, Bakan S, Kuruğoğlu S, Adaletli İ

      Abstract PURPOSE: Wilms tumor (WT) and neuroblastoma (NB) are the most common pediatric abdominal malignant neoplasms of the kidney and adrenal gland. Differentiating them from each other is essential since their treatments are different.

      Read Full Article
    19. Out-of-pocket health costs can cause financial problems for survivors of childhood cancer

      Out-of-pocket health costs can cause financial problems for survivors of childhood cancer

      Adult survivors of childhood cancer face an increased likelihood of financial difficulties related to out-of-pocket costs for their health care, compared with adults not affected by childhood cancer. In their report published online in the Journal of Clinical Oncology, investigators from the Massachusetts General Hospital (MGH) Cancer Center also report that survivors of childhood cancer who pay higher out-of-pocket costs were more than eight times more likely to have trouble paying their medical bills than were either survivors not facing higher out-of-pocket costs or adults without a history of childhood cancer.

      Read Full Article
    20. Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Aug 14;:

      Authors: Glincher R, Price AP, LaQuaglia MP, Kushner BH, Modak S

      Abstract The antivascular endothelial growth factor antibody, bevacizumab, is effective against several malignancies in adults but unproven in pediatric oncology. In early phase pediatric studies toxicities were similar to those in adults.

      Read Full Article
      Mentions: Antibody
    21. Longitudinal parental preferences for late effects communication during cancer treatment

      Few studies have investigated parent preferences for late effects communication during pediatric cancer treatment. We used questionnaire data to assess whether parental preferences for late effects information change over the year after diagnosis. Most parents found this information to be very/extremely important at baseline, assessed soon after diagnosis, (94%, 153/162), 4 months (91%, 147/162), and 12 months (96%, 156/163).

      Read Full Article
      Mentions: Treatment
    1-24 of 154 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) NANT
  4. Researches in the News

    1. (3 articles) Antibody
    2. (1 articles) MYCN
    3. (1 articles) Immunotherapy
  5. General Informations in the News

    1. (1 articles) Treatment
  6. Treatments in the News

    1. (1 articles) MIBG